A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine

Gemcitabine is associated with a broad spectrum of AEs affecting multiple organ systems, with a notable incidence of hospitalization. The study highlights both expected and unexpected AEs, which could enhance future clinical applications and safety of gemcitabine.